China Regenerative Medicine (08158.HK) released its interim results, with a net profit attributable to shareholders of 4.609 million Hong Kong dollars, a decrease of 78.15% year-on-year.

The financial news app Zhitong Finance announced that as of June 30, 2025, China Regenerative Medicine (08158.HK) released its interim performance for the six months ending on that date. The group generated revenue of 27.391 million Hong Kong dollars, a decrease of 54.18% compared to the same period last year. The net profit attributable to equity holders of the company was 4.609 million Hong Kong dollars, a decrease of 78.15% year-on-year. Earnings per share were 1.51 Hong Kong cents.